Diabetes and HIV

Overview

Journal Clin Med (Lond)

Specialty General Medicine

Date 2014 Dec 4

PMID 25468855

Citations 6

Authors

John Quin

Affiliations

Soon will be listed here.

Abstract

The co-existence of diabetes mellitus and HIV infection poses significant challenges for both patient and physician. This article reviews the clinical problems, the implications for treatment plans and potential confusions that can arise when managing patients who have both conditions.

Citing Articles

Cost analysis of adding hypertension and diabetes management into routine HIV care in Mbarara and Ibanda districts, Uganda.

Ninsiima M, Basu S, Husain M, Kawungezi P, Kabami Z, Nakafeero Simbwa B BMC Health Serv Res. 2024; 24(1):1392.

PMID: 39538306 PMC: 11559216. DOI: 10.1186/s12913-024-11825-z.

Assessing compliance with national guidelines in diabetes care: A study leveraging data from south Africa's National Health Laboratory Service (NHLS).

Brennan A, Kileel E, Fox M, George J, Khoza S, Rosen S PLOS Glob Public Health. 2024; 4(9):e0003014.

PMID: 39226276 PMC: 11371240. DOI: 10.1371/journal.pgph.0003014.

Diabetes mellitus and associated factors among HIV-positive patients at primary health care facilities in Harare, Zimbabwe: a descriptive cross-sectional study.

Chireshe R, Manyangadze T, Naidoo K BMC Prim Care. 2024; 25(1):28.

PMID: 38221613 PMC: 10789024. DOI: 10.1186/s12875-024-02261-3.

Evaluation of some immune and inflammatory responses in diabetes and HIV co-morbidity.

Chukwuanukwu R, Nwosu N, Ifeanyichukwu M, Nsonwu-Anyanwu A, Manafa P Afr Health Sci. 2023; 23(1):120-128.

PMID: 37545969 PMC: 10398510. DOI: 10.4314/ahs.v23i1.14.

Metabolic Control and Determinants Among HIV-Infected Type 2 Diabetes Mellitus Patients Attending a Tertiary Clinic in Botswana.

Rwegerera G, Shailemo D, Rivera Y, Mokgosi K, Bale P, Oyewo T Diabetes Metab Syndr Obes. 2021; 14:85-97.

PMID: 33469326 PMC: 7810972. DOI: 10.2147/DMSO.S285720.

References

Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S . Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA. 2000; 284(4):472-7. DOI: 10.1001/jama.284.4.472. View

Dube M . Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis. 2000; 31(6):1467-75. DOI: 10.1086/317491. View

Gelato M, Mynarcik D, Quick J, Steigbigel R, Fuhrer J, Brathwaite C . Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr. 2002; 31(2):163-70. DOI: 10.1097/00126334-200210010-00006. View

Fichtenbaum C, Gerber J . Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet. 2002; 41(14):1195-211. DOI: 10.2165/00003088-200241140-00004. View

Woerle H, Mariuz P, Meyer C, Reichman R, Popa E, Dostou J . Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes. 2003; 52(4):918-25. DOI: 10.2337/diabetes.52.4.918. View

Hertel J, Struthers H, Horj C, Hruz P . A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem. 2004; 279(53):55147-52. PMC: 1403823. DOI: 10.1074/jbc.M410826200. View

Lee G, Rao M, Grunfeld C . The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism. Curr Infect Dis Rep. 2004; 6(6):471-482. DOI: 10.1007/s11908-004-0067-5. View

Brown T, Cole S, Li X, Kingsley L, Palella F, Riddler S . Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005; 165(10):1179-84. DOI: 10.1001/archinte.165.10.1179. View

Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A . Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat.... Diabetes Care. 2006; 30(1):113-9. DOI: 10.2337/dc06-1075. View

10.

Fleischman A, Johnsen S, Systrom D, Hrovat M, Farrar C, Frontera W . Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab. 2007; 292(6):E1666-73. PMC: 3206591. DOI: 10.1152/ajpendo.00550.2006. View

11.

De Wit S, Sabin C, Weber R, Worm S, Reiss P, Cazanave C . Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008; 31(6):1224-9. PMC: 2746200. DOI: 10.2337/dc07-2013. View

12.

Stanley T, Grinspoon S . GH/GHRH axis in HIV lipodystrophy. Pituitary. 2008; 12(2):143-52. DOI: 10.1007/s11102-008-0092-8. View

13.

El-Zayadi A, Anis M . Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J Gastroenterol. 2012; 18(3):212-24. PMC: 3261538. DOI: 10.3748/wjg.v18.i3.212. View

14.

Palella Jr F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. DOI: 10.1056/NEJM199803263381301. View

15.

Carr A, Samaras K, Chisholm D, Cooper D . Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998; 351(9119):1881-3. DOI: 10.1016/S0140-6736(98)03391-1. View